摘要
Abstract
Objective To compare the cost-efficacy and the influence for compliance of trastuzumab injection in treating HER-2 posi-tive breast cancer. Methods 96 patients with HER-2 positive breast cancer in the hospital were randomly divided into the observation group and the control group,48 cases in each group. The control group was treated with CAF regimen,the observation group was treated with trastuzumab. Both groups were treated 18 weeks. The clinical effect was compared,the level of the tumor marker and the length of solid tumor were detected and recorded,the cost-efficacy analysis of these two observation were calculated by the method of eco-nomics,the score of KPS and the compliance and the adverse reactions during the observation were observed. Results After treatment, the total effective rate of the observation group were 60. 42%,which was significantly higher than 41. 67% of the control group( P < 0. 05). Compared with the control group,the length of solid tumor in the observation group were shorten( P < 0. 05),and the level of the tu-mor marker CEA,CA153,CA125 were decreased( P < 0. 05);the cost-efficacy ratio in the observation group was 1 131. 36,which was significantly lower than 1 500. 71 in the control group( P < 0. 05),if the control group wanted to increase the effective rate,about 19. 70 yuan should be added to. The improvement rate of KPS in the observation group were 89. 58%,which was significantly higher than 81. 25% of the control group( P < 0. 05). The compliance and adverse reactions rate had no significantly difference in the two groups( P > 0. 05). Conclusion Trastuzumab for treating HER-2 positive breast cancer has good effect,and can reduce the level of the tumor marker,the cost-efficacy analysis were superior to the CAF regimen. It can improve the survival quality of the patients with good compliance,and has less adverse reactions,which is worthy of clinical promotion.关键词
人表皮生长因子受体2/乳腺癌/曲妥珠单抗/环磷酰胺/多柔比星/氟尿嘧啶/成本-效果/用药依从性Key words
HER-2/breast cancer/Trastuzumab/Cyclophosphamide/Doxorubicin/Fluorouracil/cost-efficacy analysis/medication compliance分类
药学
